Patents Assigned to Novartis Pharmaceuticals Corporation
  • Publication number: 20070293482
    Abstract: A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R1 represents C1-6 alkyl, aryl or heteroaryl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, —CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R?, wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; n is from 0 to 3; X represents —NH—, —N(C1-C6alkyl)-, —CO—, —CO—NR?—, —S(O)— or —S(O)2—, wherein R? is hydrogen or a C1-C6 alkyl group; and R4 represents hydrogen; or —CO—R4? or —CO—NH—R4 ?, wherein R4 ? is a C1-C6 alkyl, C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a —(C1-C4 alkyl)-X1—(C1-C4 alkyl)-X2—(C1-C4 alkyl) group, wherein X1 represents —
    Type: Application
    Filed: March 21, 2005
    Publication date: December 20, 2007
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Verity Dowdell, Richard Kelsey, Malcolm Carter, Elisa Henderson
  • Publication number: 20070185096
    Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
    Type: Application
    Filed: March 18, 2005
    Publication date: August 9, 2007
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Verity Dowdell, Dagmar Alber, Elisa Henderson
  • Publication number: 20060216204
    Abstract: A sensor platform for use in sample analysis comprises a substrate (30) of refractive index (n1) and a thin, optically transparent layer (32) of refractive index (n2) on the substrate, (n2) is greater than (n1). The platform incorporates one or multiple corrugated structures in the form of periodic grooves (31), (33), which defines one or more sensing areas each for one or more capture elements. The grooves are so profiled, dimensioned and oriented that when coherent light is incident on the platform it is diffracted into individual beams or diffraction order resulting in reduction of the transmitted beam and an abnormal high reflection of the incident light thereby creates an enhanced evanescent field at the surface of the or each sensing area. The amplitude of this field at the resonant condition is greater by an order of approximately 100 than the field of prior art platforms so that the luminescence intensity created from samples on the platform is also increased by a factor of 100.
    Type: Application
    Filed: February 8, 2006
    Publication date: September 28, 2006
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Wolfgang Ernst Budach, Dieter Neuschaefer
  • Publication number: 20050117161
    Abstract: A sensor platform for use in sample analysis comprises a substrate (30) of refractive index (n1) and a thin, optically transparent layer (32) of refractive index (n2) on the substrate, (n2 is greater than (n1). The platform incorporates one or multiple corrugated structures in the form of periodic grooves (31), (33), which defines one or more sensing areas each for one or more capture elements. The grooves are so profiled, dimensioned and oriented that when coherent light is incident on the platform it is diffracted into individual beams or diffraction order resulting in reduction of the transmitted beam and an abnormal high reflection of the incident light thereby creates an enhanced evanescent field at the surface of the or each sensing area. The amplitude of this field at the resonant condition is greater by an order of approximately 100 than the field of prior art platforms so that the luminescence intensity created from samples on the platform is also increased by a factor of 100.
    Type: Application
    Filed: November 8, 2004
    Publication date: June 2, 2005
    Applicant: Novartis Pharmaceuticals Corporation
    Inventors: Wolfgang Budach, Dieter Neuschaefer
  • Publication number: 20040241706
    Abstract: This invention provides methods and compositions related to modified GTPase sequences and GTPase modulators.
    Type: Application
    Filed: September 10, 2003
    Publication date: December 2, 2004
    Applicants: IRM, LLC, Novartis Pharmaceuticals Corporation
    Inventors: Kavita Shah, Fabien Vincent, Maria A. Cueto
  • Patent number: 5753675
    Abstract: Quinoline analogs of mevalonolactone of the following formula are useful as anti-cholesterol synthesis agents: ##STR1## where the substituents are as defined in the specification.
    Type: Grant
    Filed: March 23, 1990
    Date of Patent: May 19, 1998
    Assignee: Novartis Pharmaceuticals Corporation
    Inventor: Sompong Wattanasin